Posted by Michael Wonder on 07 Aug 2024
Abaloparatide for the treatment of women with osteoporosis after menopause
6 August 2024 - NICE has issued dvidence-based recommendations on the use of abaloparatide (Eladynos) for treatment of osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.
Abaloparatide is recommended as an option for treating osteoporosis after menopause in women, trans men and non-binary people, only if they have a very high risk of fracture. It is only recommended if the company provides it according to the commercial arrangement.
